1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > ADC Therapeutics SA - Product Pipeline Review - 2016

ADC Therapeutics SA - Product Pipeline Review - 2016

  • November 2016
  • -
  • Global Markets Direct
  • -
  • 34 pages

ADC Therapeutics SA - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘ADC Therapeutics SA - Product Pipeline Review - 2016’, provides an overview of the ADC Therapeutics SA’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by ADC Therapeutics SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of ADC Therapeutics SA
- The report provides overview of ADC Therapeutics SA including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses ADC Therapeutics SA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features ADC Therapeutics SA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate ADC Therapeutics SA’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for ADC Therapeutics SA
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding ADC Therapeutics SA’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

ADC Therapeutics SA - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
ADC Therapeutics SA Snapshot 5
ADC Therapeutics SA Overview 5
Key Facts 5
ADC Therapeutics SA - Research and Development Overview 6
Key Therapeutic Areas 6
ADC Therapeutics SA - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
ADC Therapeutics SA - Pipeline Products Glance 11
ADC Therapeutics SA - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
ADC Therapeutics SA - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
ADC Therapeutics SA - Drug Profiles 14
ADCT-301 - Drug Profile 14
Product Description 14
Mechanism Of Action 14
RandD Progress 14
ADCT-401 - Drug Profile 16
Product Description 16
Mechanism Of Action 16
RandD Progress 16
ADCT-402 - Drug Profile 17
Product Description 17
Mechanism Of Action 17
RandD Progress 17
ADCT-501 - Drug Profile 19
Product Description 19
Mechanism Of Action 19
RandD Progress 19
ADCT-502 - Drug Profile 20
Product Description 20
Mechanism Of Action 20
RandD Progress 20
ADCT-601 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
RandD Progress 21
Monoclonal Antibody Conjugate for Oncology - Drug Profile 22
Product Description 22
Mechanism Of Action 22
RandD Progress 22
Monoclonal Antibody Conjugate to Target CD22 for Non Hodgkin's Lymphoma - Drug Profile 23
Product Description 23
Mechanism Of Action 23
RandD Progress 23
Monoclonal Antibody Conjugates 1 for Oncology - Drug Profile 24
Product Description 24
Mechanism Of Action 24
RandD Progress 24
Monoclonal Antibody Conjugates to Target PSMA for Prostate Cancer - Drug Profile 25
Product Description 25
Mechanism Of Action 25
RandD Progress 25
VM-101 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
RandD Progress 26
ADC Therapeutics SA - Pipeline Analysis 27
ADC Therapeutics SA - Pipeline Products by Target 27
ADC Therapeutics SA - Pipeline Products by Route of Administration 28
ADC Therapeutics SA - Pipeline Products by Molecule Type 29
ADC Therapeutics SA - Pipeline Products by Mechanism of Action 30
ADC Therapeutics SA - Dormant Projects 31
ADC Therapeutics SA - Locations And Subsidiaries 32
Head Office 32
Other Locations and Subsidiaries 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables
ADC Therapeutics SA, Key Facts 5
ADC Therapeutics SA - Pipeline by Indication, 2016 8
ADC Therapeutics SA - Pipeline by Stage of Development, 2016 9
ADC Therapeutics SA - Monotherapy Products in Pipeline, 2016 10
ADC Therapeutics SA - Phase I, 2016 11
ADC Therapeutics SA - Preclinical, 2016 12
ADC Therapeutics SA - Discovery, 2016 13
ADC Therapeutics SA - Pipeline by Target, 2016 27
ADC Therapeutics SA - Pipeline by Route of Administration, 2016 28
ADC Therapeutics SA - Pipeline by Molecule Type, 2016 29
ADC Therapeutics SA - Pipeline Products by Mechanism of Action, 2016 30
ADC Therapeutics SA - Dormant Developmental Projects,2016 31
ADC Therapeutics SA, Other Locations 32

List of Figures
ADC Therapeutics SA - Pipeline by Top 10 Indication, 2016 7
ADC Therapeutics SA - Pipeline by Stage of Development, 2016 9
ADC Therapeutics SA - Monotherapy Products in Pipeline, 2016 10
ADC Therapeutics SA - Pipeline by Target, 2016 27
ADC Therapeutics SA - Pipeline by Molecule Type, 2016 29
ADC Therapeutics SA - Pipeline Products by Mechanism of Action, 2016 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Pipeline Review, H2 20

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Pipeline Review, H2 20

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B o ...

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H2 2016

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Ephrin Type A Receptor 2 (Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Ephrin Type A Recepto ...

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase CSK (C Src Kinase ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.